A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

NCT00001076 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: ALVAC-HIV MN120TMG (vCP205)
BIOLOGICAL: ALVAC-RG Rabies Glycoprotein (vCP65)
BIOLOGICAL: rgp120/HIV-1 SF-2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)